CMO option grant at Milestone (MIST) corrected to $1.96 exercise price
Rhea-AI Filing Summary
Milestone Pharmaceuticals Inc. reported an amended insider transaction for its Chief Medical Officer. The officer received an employee stock option to buy 204,000 common shares at an exercise price of $1.96 per share, granted on February 2, 2026 and expiring on February 2, 2036.
The amendment corrects an initially misstated exercise price. One-fourth of the option shares vest on February 2, 2027, with one thirty-sixth of the remaining shares vesting monthly thereafter, as long as the officer continues providing services.
Positive
- None.
Negative
- None.
Insider Trade Summary
1 transaction reported
Mixed
1 txn
Insider
Bharucha David
Role
Chief Medical Officer
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Employee Stock Option (right to buy) | 204,000 | $0.00 | -- |
Holdings After Transaction:
Employee Stock Option (right to buy) — 204,000 shares (Direct)
Footnotes (1)
- The exercise price on the initial filings was incorrectly stated. One-fourth (1/4th) of the shares subject to the option vest on February 2, 2027, and one thirty-sixth (1/36th) of the remaining shares subject to this option shall vest each month thereafter, subject to the Reporting Person continuing to provide service through each such date.
AI-generated analysis. How Rhea-AI works. Not financial advice.
FAQ
What insider transaction did Milestone Pharmaceuticals (MIST) report?
Milestone Pharmaceuticals reported an amended insider transaction granting its Chief Medical Officer an employee stock option for 204,000 common shares at an exercise price of $1.96 per share, correcting an error in the originally reported exercise price.
Why was this Form 4/A amendment filed for Milestone Pharmaceuticals (MIST)?
The Form 4/A was filed to correct the exercise price on the initial filings, which the company states was incorrectly reported. The amended filing specifies an accurate exercise price of $1.96 per share for the employee stock option grant.
How many stock options were granted to the Milestone Pharmaceuticals CMO?
The Chief Medical Officer received an employee stock option covering 204,000 common shares. These options were granted on February 2, 2026, with all 204,000 shares underlying the derivative security and expiring on February 2, 2036.
What is the vesting schedule for the Milestone Pharmaceuticals CMO’s options?
The vesting schedule provides that one-fourth of the option shares vest on February 2, 2027. Thereafter, one thirty-sixth of the remaining shares vests each month, assuming the reporting person continues to provide service through each vesting date.
What is the expiration date of the Milestone Pharmaceuticals (MIST) CMO’s option grant?
The employee stock option granted to the Chief Medical Officer expires on February 2, 2036. Until that date, subject to vesting and continued service requirements, the holder may exercise the option at the corrected $1.96 per-share exercise price.
How many derivative securities does the Milestone Pharmaceuticals CMO own after this transaction?
Following the reported transaction, the Chief Medical Officer beneficially owns 204,000 derivative securities in the form of employee stock options. These options relate to 204,000 common shares and are reported as held with direct ownership.